Literature DB >> 17880852

New drugs to treat skin and soft tissue infections.

Gary E Stein1.   

Abstract

Due to increasing antimicrobial resistance, a pressing need exists for new antibiotics to treat skin and soft tissue infections. Several newer agents such as tigecycline, daptomycin, and linezolid have been important additions for the treatment of multidrug-resistant pathogens. New drugs in development such as dalbavancin and ceftobiprole will further enhance our ability to treat mixed infections and improve patient compliance. These promising new antimicrobials will likely grow in importance as resistant bacterial strains increase in community-acquired infections.

Entities:  

Year:  2007        PMID： 17880852     DOI： 10.1007/s11908-007-0063-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  50 in total

Review 1.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

2.  Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.

Authors:  Ronald N Jones; James E Ross; Thomas R Fritsche; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2005-12-02       Impact factor: 5.790

3.  In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.

Authors:  F García-Garrote; E Cercenado; L Alcalá; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

Authors:  E J Ellis-Grosse; T Babinchak; N Dartois; G Rose; E Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

Review 5.  Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.

Authors:  C H Nightingale
Journal:  Pharmacotherapy       Date:  2000-03       Impact factor: 4.705

6.  Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Authors:  M Chen; A N Nafziger; G L Drusano; L Ma; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.

Authors:  P Hebeisen; I Heinze-Krauss; P Angehrn; P Hohl; M G Page; R L Then
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

Authors:  John Weigelt; Kamal Itani; Dennis Stevens; William Lau; Matthew Dryden; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

9.  Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.

Authors:  Martin E Stryjewski; Vivian H Chu; William D O'Riordan; Brian L Warren; Lala M Dunbar; David M Young; Marc Vallée; Vance G Fowler; Joel Morganroth; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

Review 10.  Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.

Authors:  David E Nix; Anup K Majumdar; Mark J DiNubile
Journal:  J Antimicrob Chemother       Date:  2004-06       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.